Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 6/20 | 0.58 |
| ▸ | CA1 | P00915 | 6/20 | 0.58 |
| ▸ | CA2 | P00918 | 6/20 | 0.58 |
| ▸ | CA9 | Q16790 | 6/20 | 0.58 |
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7525285 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL598026 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL3422180 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL5133849 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL2819924 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL7908254 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL5193445 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL15508929 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL22777078 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL29040489 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 481 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223851-B2 | Nucleic acid-binding polymers | GENERAL DYNAMICS ADVANCED INFORMATION SYSTEMS, INC. (US) | 2007-05-29 | — | — | US | claimed |
| US-20040157217-A1 | Nucleic acid-binding polymers | VERIDIAN SYSTEMS DIVISION | 2004-08-12 | — | — | US | claimed |
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026087635-A1 | DIHYDRO BENZOXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| US-20260085062-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260041776-A1 | POLYMER CONTRAST AGENT | KOWA COMPANY, LTD. (JP) | 2026-02-12 | — | — | US | disclosed |
| US-12517130-B2 | Isoindoline derivatives which bind to an ATP binding site | Neophore Limited (GB) | 2026-01-06 | — | — | US | disclosed |
| WO-1995032954-A1 | EPOXYSUCCINIC ACID DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-12-07 | — | — | WO | disclosed |
| WO-1995018105-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-07-06 | — | — | WO | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| US-5047430-A | Glutamate Receptor Inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0278621-B1 | SUBSTITUTED AMINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1991-06-12 | — | — | EP | disclosed |
| US-4990511-A | Amide compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-02-05 | — | — | US | disclosed |
| EP-0353753-A1 | Amide compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-02-07 | — | — | EP | disclosed |
| EP-0339927-A2 | Amide compounds their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-11-02 | — | — | EP | disclosed |
| EP-0229944-A2 | Novel tetrahydroisoquinoline derivatives | SYNTEX (U.S.A.) INC. (US) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041776-A1 | POLYMER CONTRAST AGENT | RXFP3, HAX1, MSR1 | TDP1 2333/4885MAOA 3051/4885MAOB 3518/4885 |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | TDP1 3638/4885MAOA 3362/4885MAOB 3364/4885 |
| US-20260085062-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK1G1, CSNK2A3 | TDP1 2279/4885MAOA 4461/4885MAOB 4211/4885 |
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK2A3, CSNK1G1 | TDP1 2438/4885MAOA 4502/4885MAOB 4075/4885 |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | TDP1 3181/4885MAOA 2140/4885MAOB 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.